Kathleen Moore
MD, MS
Associate Director of Clinical Research
Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Kathleen Moore is the Virginia Kerley Cade Endowed Chair in Cancer Development and Professor of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Oklahoma Health Sciences Center. She currently serves as the Associate Director of Clinical Research and the Director of the Oklahoma TSET Phase I Program at the Stephenson Cancer Center. She also serves as the Associate Program Director of the Gyn Oncology Fellowship Program in the Section of Gyn Oncology of the Department of OB/GYN. She completed her gyn oncology fellowship at the University of Oklahoma Health Sciences Center in 2007 and was recruited to join the faculty. Her primary areas of interest are in new drug development and Phase I clinical trials.

Sessions

Register
General Session

Session 16: Debate: In What Setting Should Immune Checkpoint Inhibitors (ICIs) Be Incorporated into the Treatment of Endometrial Cancer? - DISCUSSION

Saturday, May 04, 2024
4:25 PM - 4:35 PM
General Session

Debate: What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: Locally Advanced Cervical Cancer or in Combination with Chemotherapy in the First-Line Metastatic Setting? - DISCUSSION

Friday, November 01, 2024
2:05 PM - 2:15 PM
General Session

Case Discussions

Friday, November 01, 2024
2:15 PM - 2:55 PM
General Session

Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease? Platinum is the SOC vs It's Time to Move on From Platinum - DISCUSSION

Friday, November 01, 2024
4:35 PM - 4:45 PM
General Session

Debate: Immune-Checkpoint Inhibitors Should Be Used: With and to Follow Chemotherapy in All Patients with Advanced Endometrial Cancer - Irrespective of Biomarker vs Only in dMMR in the Front Line. pMMR Should Receive In Recurrent Setting with Lenvatinib

Friday, November 01, 2024
5:15 PM - 5:25 PM
General Session

Debate: Front Line Maintenance Therapy for Advanced Ovarian Cancer: Everyone Should Be Offered PARPi vs. New Opportunities Beyond PARPi – DISCUSSION

Saturday, November 02, 2024
2:45 PM - 2:55 PM
General Session

Q&A Panel

Saturday, November 02, 2024
3:40 PM - 3:50 PM
General Session

ADC Abundance: Leveraging Other Solid Tumor Experience to Guide Development of Sequencing and Biomarkers in Gynecologic Cancers

Saturday, November 02, 2024
4:05 PM - 4:20 PM
General Session

Q&A Panel

Saturday, November 02, 2024
4:20 PM - 4:30 PM